Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Theravance Biopharma ( (TBPH) ).
At the 2025 Annual General Meeting held on May 19, Theravance Biopharma shareholders elected Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, a non-binding advisory resolution on executive compensation was approved, reflecting shareholder support for the company’s leadership and financial oversight.
The most recent analyst rating on (TBPH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s overall score reflects financial challenges due to consistent losses and negative margins, despite strong sales growth and strategic advancements noted in the earnings call. The technical analysis indicates a lack of strong directional momentum. Valuation metrics remain weak due to negative earnings. Despite a solid cash position and progress in trials, increased operating expenses and pending litigation weigh on the outlook.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines for respiratory diseases, gastrointestinal disorders, and infectious diseases.
Average Trading Volume: 275,303
Technical Sentiment Signal: Hold
Current Market Cap: $469.5M
See more insights into TBPH stock on TipRanks’ Stock Analysis page.